isoniazid has been researched along with Body Weight in 85 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 8.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| "Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment." | 7.81 | A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. ( Choi, R; Jeon, K; Jeong, BH; Jung, JA; Kim, TE; Ko, JW; Koh, WJ; Kwon, OJ; Lee, H; Lee, SY; Park, HY; Woo, HI, 2015) |
| "In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients." | 7.70 | Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999) |
| "Pharmacokinetic studies in the past have shown inadequate antituberculosis drug levels in children with the currently available dosing regimens." | 6.90 | Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. ( Aruldhas, BW; Bose, A; Hoglund, RM; Mathew, BS; Mathew, SK; Ranjalkar, J; Tarning, J; Verghese, VP, 2019) |
| "Significant pharmacokinetic variabilities have been reported for isoniazid across various populations." | 6.82 | Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. ( Banerjee, M; M, SS; Mallayasamy, S; Raju, AP; Rao, M; Saravu, K; Sv, CS; Thomas, L; Varma, M, 2022) |
| "Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges." | 4.98 | Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. ( Atwine, D; Bonnet, M; Taburet, AM, 2018) |
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 4.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| " We estimated tuberculosis treatment outcomes in children younger than 5 years following WHO guidelines (children are dosed by weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: one based on a proposed algorithm that uses age, weight, and available formulations, in which underweight children would receive the same drug doses as would normal weight children of the same age; and another based on an individualised algorithm without dose limitations, in which derived doses results in target exposure attainment for the typical child." | 3.91 | Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. ( Dodd, PJ; Dooley, KE; Garcia-Prats, AJ; Hesseling, AC; McKenna, L; Radtke, KK; Savic, RM, 2019) |
| "Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment." | 3.81 | A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. ( Choi, R; Jeon, K; Jeong, BH; Jung, JA; Kim, TE; Ko, JW; Koh, WJ; Kwon, OJ; Lee, H; Lee, SY; Park, HY; Woo, HI, 2015) |
| " The major revision was to increase isoniazid, rifampicin and pyrazinamide dosages according to body weight in children." | 3.81 | The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. ( Gie, RP; Graham, SM; Grzemska, M, 2015) |
| " The objectives of this investigation were to evaluate the impact of body weight on the overall systemic exposure to pyrazinamide (PZA) and to assess whether the use of one fixed dose, without adjustment according to weight, would ensure target exposure and safety requirements across the overall patient population." | 3.78 | Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. ( Della Pasqua, O; Sahota, T, 2012) |
| "In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients." | 3.70 | Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999) |
| "An analysis carried out on the dosage schemes adopted in several controlled clinical trials in tuberculosis has indicated that preestablishing the daily doses of isoniazid, rifampicin, and pyrazinamide in the initial intensive phase results in large deviations of the doses administered from those considered appropriate in mg/kg body weight." | 3.67 | Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase. ( Acocella, G; Angel, JH, 1986) |
| " We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and efavirenz in pregnant women." | 3.01 | Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. ( Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Browning, R; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Hesseling, A; Jean-Philippe, P; Kabugho, E; Masheto, GR; McCarthy, K; Mhembere, T; Mmbaga, BT; Montepiedra, G; Mutambanengwe, M; Nevrekhar, N; Norman, J; Nyati, M; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Tongprasert, F; Vhembo, T; Violari, A; Wallis, CL; Weinberg, A; Wiesner, L; Zimmer, B, 2021) |
| "Pharmacokinetic studies in the past have shown inadequate antituberculosis drug levels in children with the currently available dosing regimens." | 2.90 | Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. ( Aruldhas, BW; Bose, A; Hoglund, RM; Mathew, BS; Mathew, SK; Ranjalkar, J; Tarning, J; Verghese, VP, 2019) |
| "Significant pharmacokinetic variabilities have been reported for isoniazid across various populations." | 2.82 | Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. ( Banerjee, M; M, SS; Mallayasamy, S; Raju, AP; Rao, M; Saravu, K; Sv, CS; Thomas, L; Varma, M, 2022) |
| "Among persons who were underweight at diagnosis, weight gain of 5% or less between diagnosis and completion of 2-mo intensive phase therapy was moderately associated with an increased relapse risk (18." | 2.72 | Lack of weight gain and relapse risk in a large tuberculosis treatment trial. ( Horsburgh, CR; Khan, A; Reves, R; Sterling, TR; Vernon, A, 2006) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| "Rifampin is a key sterilizing drug in the treatment of tuberculosis (TB)." | 1.43 | Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2016) |
| "Isoniazid (INH) is a widely used drug in the prophylaxis and treatment of tuberculosis." | 1.42 | Circadian-time dependent tolerance and haematological toxicity to isoniazid in murine. ( Aouam, K; Ben Attia, M; Boughattas, F; Boughattas, NA; Chennoufi, M; Hassine, M; Reinberg, A; Souayed, N, 2015) |
| " The proportion of patients treated with consistent dosing of a 3-drug fixed-dose combination (FDC) increased from 73." | 1.38 | Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan. ( Bai, KJ; Chiang, CY; Hsu, YL; Lin, TP; Shih, HC; Yang, SL; Yen, MY; Yu, MC, 2012) |
| " Bioavailability was expressed as an index (BI) of area under time concentration curve (AUC) calculated from the plasma concentrations or proportion of dose of R excreted as R plus DR in urine with the combinations to that with R alone." | 1.32 | Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. ( Chandrasekaran, V; Gurumurthy, P; Immanuel, C; Prabhakar, R; Ramachandran, G; Venkatesan, P, 2003) |
| "All 44 non-private hospitals in Malawi treating pulmonary tuberculosis (PTB) patients with an oral regimen (0." | 1.32 | Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi. ( Gausi, F; Harries, AD; Salaniponi, FM, 2004) |
| " The LD50 values of PIH in both species were 5 and 1 g/kg given orally and intraperitoneally, respectively." | 1.28 | Toxicological study of pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity. ( Nakornchai, S; Sookvanichsilp, N; Weerapradist, W, 1991) |
| "3 micrograms/ml or less by body-weight-related dosage and 0." | 1.28 | Classification of children as slow or rapid acetylators based on concentrations of isoniazid in saliva following oral administration of body-weight and surface-area-related dosages of the drug. ( Datta, M; Kailasam, S; Loganathan, GK; Narayana, AS; Rahman, F; Sarma, GR, 1990) |
| " Usefully results are obtained after application per os of an uniform dosage and a sampling period for urine of 4 hours." | 1.26 | [The different inactivation of isoniazid in intermittent chemotherapy (author's transl)]. ( Eule, H; Fischer, P; Franke, H; Iwainsky, H; Werner, E; Winsel, K, 1977) |
| " None of the doses of BCG CW used was toxic and they were at least as effective as living BCG in intralesional treatment." | 1.26 | Safety and efficacy of living BCG or BCG cell walls (CW) in the treatment of guinea pig hepatoma. ( Canti, G; Hunter, J; Rapp, HJ; Zbar, B, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 53 (62.35) | 18.7374 |
| 1990's | 7 (8.24) | 18.2507 |
| 2000's | 6 (7.06) | 29.6817 |
| 2010's | 16 (18.82) | 24.3611 |
| 2020's | 3 (3.53) | 2.80 |
| Authors | Studies |
|---|---|
| Chaturvedi, AK | 1 |
| Verma, AK | 1 |
| Thakur, JP | 1 |
| Roy, S | 1 |
| Bhushan Tripathi, S | 1 |
| Kumar, BS | 1 |
| Khwaja, S | 1 |
| Sachan, NK | 1 |
| Sharma, A | 1 |
| Chanda, D | 1 |
| Shanker, K | 1 |
| Saikia, D | 1 |
| Negi, AS | 1 |
| Thomas, L | 1 |
| Raju, AP | 1 |
| M, SS | 1 |
| Varma, M | 1 |
| Saravu, K | 1 |
| Banerjee, M | 1 |
| Sv, CS | 1 |
| Mallayasamy, S | 1 |
| Rao, M | 1 |
| Jarrett, RT | 1 |
| van der Heijden, Y | 1 |
| Shotwell, MS | 1 |
| Chihota, V | 1 |
| Marzinke, MA | 1 |
| Chaisson, RE | 1 |
| Dooley, KE | 3 |
| Churchyard, GJ | 1 |
| Gausi, K | 1 |
| Wiesner, L | 1 |
| Norman, J | 1 |
| Wallis, CL | 1 |
| Onyango-Makumbi, C | 1 |
| Chipato, T | 1 |
| Haas, DW | 1 |
| Browning, R | 1 |
| Chakhtoura, N | 1 |
| Montepiedra, G | 1 |
| Aaron, L | 1 |
| McCarthy, K | 1 |
| Bradford, S | 1 |
| Vhembo, T | 1 |
| Stranix-Chibanda, L | 1 |
| Masheto, GR | 1 |
| Violari, A | 1 |
| Mmbaga, BT | 1 |
| Aurpibul, L | 1 |
| Bhosale, R | 1 |
| Nevrekhar, N | 1 |
| Rouzier, V | 1 |
| Kabugho, E | 1 |
| Mutambanengwe, M | 1 |
| Chanaiwa, V | 1 |
| Nyati, M | 1 |
| Mhembere, T | 1 |
| Tongprasert, F | 1 |
| Hesseling, A | 1 |
| Shin, K | 1 |
| Zimmer, B | 1 |
| Costello, D | 1 |
| Jean-Philippe, P | 1 |
| Sterling, TR | 2 |
| Theron, G | 1 |
| Weinberg, A | 1 |
| Gupta, A | 2 |
| Denti, P | 2 |
| Guiastrennec, B | 1 |
| Ramachandran, G | 2 |
| Karlsson, MO | 1 |
| Kumar, AKH | 1 |
| Bhavani, PK | 1 |
| Gangadevi, NP | 1 |
| Swaminathan, S | 1 |
| Savic, RM | 2 |
| Atwine, D | 1 |
| Bonnet, M | 1 |
| Taburet, AM | 1 |
| Chen, YQ | 1 |
| Du, J | 1 |
| Liu, YH | 1 |
| Sun, ZG | 1 |
| Ma, Y | 1 |
| Shu, W | 1 |
| Lyu, XY | 1 |
| Tian, XZ | 1 |
| Li, L | 1 |
| Gao, WW | 1 |
| Aruldhas, BW | 1 |
| Hoglund, RM | 1 |
| Ranjalkar, J | 1 |
| Tarning, J | 1 |
| Mathew, SK | 1 |
| Verghese, VP | 1 |
| Bose, A | 1 |
| Mathew, BS | 1 |
| Radtke, KK | 1 |
| Dodd, PJ | 1 |
| Garcia-Prats, AJ | 1 |
| McKenna, L | 1 |
| Hesseling, AC | 1 |
| Sabina, EP | 1 |
| Peter S, J | 1 |
| S, P | 1 |
| Geetha, A | 1 |
| Lodha, R | 1 |
| Mukherjee, A | 1 |
| Singh, V | 1 |
| Singh, S | 1 |
| Friis, H | 1 |
| Faurholt-Jepsen, D | 1 |
| Bhatnagar, S | 1 |
| Saini, S | 1 |
| Kabra, SK | 1 |
| Grewal, HM | 1 |
| Souayed, N | 1 |
| Chennoufi, M | 1 |
| Boughattas, F | 1 |
| Hassine, M | 1 |
| Ben Attia, M | 1 |
| Aouam, K | 1 |
| Reinberg, A | 1 |
| Boughattas, NA | 1 |
| Jung, JA | 1 |
| Kim, TE | 1 |
| Lee, H | 1 |
| Jeong, BH | 1 |
| Park, HY | 1 |
| Jeon, K | 1 |
| Kwon, OJ | 1 |
| Ko, JW | 1 |
| Choi, R | 1 |
| Woo, HI | 1 |
| Koh, WJ | 1 |
| Lee, SY | 1 |
| Chirehwa, MT | 1 |
| Rustomjee, R | 1 |
| Mthiyane, T | 1 |
| Onyebujoh, P | 1 |
| Smith, P | 1 |
| McIlleron, H | 1 |
| Graham, SM | 1 |
| Grzemska, M | 1 |
| Gie, RP | 1 |
| Sturkenboom, MG | 1 |
| Akkerman, OW | 1 |
| van Altena, R | 1 |
| de Lange, WC | 1 |
| Kosterink, JG | 1 |
| van der Werf, TS | 1 |
| Alffenaar, JC | 1 |
| Adhvaryu, MR | 1 |
| Reddy, N | 1 |
| Vakharia, BC | 1 |
| Fahimi, F | 1 |
| Kobarfard, F | 1 |
| Tabarsi, P | 1 |
| Hemmati, S | 1 |
| Salamzadeh, J | 1 |
| Baniasadi, S | 1 |
| Sahota, T | 1 |
| Della Pasqua, O | 1 |
| Chiang, CY | 1 |
| Yu, MC | 1 |
| Shih, HC | 1 |
| Yen, MY | 1 |
| Hsu, YL | 1 |
| Yang, SL | 1 |
| Lin, TP | 1 |
| Bai, KJ | 1 |
| FALOON, WW | 1 |
| MUDIE, IS | 1 |
| HORNE, NW | 1 |
| CROFTON, JW | 1 |
| DONNO, L | 1 |
| BELL, WJ | 1 |
| BROWN, PP | 1 |
| Hendrickson, RF | 1 |
| Alvares, AP | 1 |
| Visek, WJ | 1 |
| ROBOZ, P | 1 |
| KADAR, M | 1 |
| RAMAKRISHNAN, CV | 2 |
| RAJENDRAN, K | 1 |
| JACOB, PG | 1 |
| FOX, W | 3 |
| RADHAKRISHNA, S | 2 |
| Immanuel, C | 1 |
| Gurumurthy, P | 1 |
| Venkatesan, P | 1 |
| Chandrasekaran, V | 1 |
| Prabhakar, R | 1 |
| Harries, AD | 1 |
| Gausi, F | 1 |
| Salaniponi, FM | 1 |
| Rana, SV | 2 |
| Pal, R | 1 |
| Vaiphie, K | 1 |
| Singh, K | 2 |
| Khan, A | 1 |
| Reves, R | 1 |
| Vernon, A | 1 |
| Horsburgh, CR | 1 |
| Botta, JA | 1 |
| Carlton, WW | 1 |
| Chaulet, P | 1 |
| Larbaoui, D | 1 |
| Grosset, J | 1 |
| Abderrahim, K | 1 |
| Bender, DA | 1 |
| Romá, J | 1 |
| Soria, B | 1 |
| Nouhouayi, A | 1 |
| Koukol, SC | 1 |
| DeHaven, JI | 1 |
| Riggs, DR | 1 |
| Lamm, DL | 1 |
| Anglaret, X | 1 |
| Saba, J | 1 |
| Perronne, C | 1 |
| Lacassin, F | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Vildé, JL | 1 |
| Durrheim, DN | 1 |
| Belt, EL | 1 |
| Cakir, B | 1 |
| Yönem, A | 1 |
| Güler, S | 1 |
| Odabaşi, E | 1 |
| Demirbaş, B | 1 |
| Gürsoy, G | 1 |
| Aral, Y | 1 |
| Attri, S | 1 |
| Vaiphei, K | 1 |
| Sodhi, CP | 1 |
| Katyal, R | 1 |
| Goel, RC | 1 |
| Nain, CK | 1 |
| Sotaniemi, S | 1 |
| Iwainsky, H | 1 |
| Eule, H | 1 |
| Fischer, P | 1 |
| Werner, E | 1 |
| Winsel, K | 1 |
| Franke, H | 1 |
| Zbar, B | 1 |
| Hunter, J | 1 |
| Rapp, HJ | 1 |
| Canti, G | 1 |
| Matthiessen, W | 1 |
| Wundschock, M | 1 |
| Radenbach, KL | 1 |
| Göbel, D | 1 |
| Jungbluth, H | 1 |
| Kropp, R | 1 |
| Golli, V | 1 |
| Sfârlează, V | 1 |
| Ionescu, N | 1 |
| Stefănescu, I | 1 |
| Stefanin, E | 1 |
| Kraemer, GW | 1 |
| McKinney, WT | 1 |
| Prange, AJ | 1 |
| Breese, GR | 1 |
| McMurray, TM | 1 |
| Kemnitz, J | 1 |
| Barbera, A | 1 |
| Borja, H | 1 |
| Barbera, L | 1 |
| Masoli, P | 1 |
| Sookvanichsilp, N | 1 |
| Nakornchai, S | 1 |
| Weerapradist, W | 1 |
| Sarma, GR | 1 |
| Kailasam, S | 1 |
| Datta, M | 1 |
| Loganathan, GK | 1 |
| Rahman, F | 1 |
| Narayana, AS | 1 |
| Plummer, JL | 1 |
| Hall, PD | 1 |
| Jenner, MA | 1 |
| Cmielewski, PL | 1 |
| Ilsley, AH | 1 |
| Cousins, MJ | 1 |
| Rice, SA | 1 |
| Maze, M | 1 |
| Smith, CM | 1 |
| Kosek, JC | 1 |
| Mazze, RI | 1 |
| Acocella, G | 1 |
| Angel, JH | 1 |
| Santoso, B | 1 |
| Stott, RB | 1 |
| Mallinson, CN | 1 |
| Pyle, MM | 1 |
| Tousek, J | 1 |
| Votruba, R | 1 |
| Ashba, JK | 1 |
| Boyce, JM | 1 |
| Devi, S | 1 |
| Desai, M | 1 |
| Jariwala, G | 1 |
| Khokhani, B | 1 |
| Desai, NK | 1 |
| Sheth, UK | 1 |
| Ellard, GA | 1 |
| Gammon, PT | 1 |
| Polansky, F | 1 |
| Víznerová, A | 1 |
| Havlík, I | 1 |
| Devadatta, S | 1 |
| Evans, C | 1 |
| Menon, NK | 1 |
| Nazareth, O | 1 |
| Sambamoorthy, S | 1 |
| Stott, H | 1 |
| Tripathy, SP | 1 |
| Velu, S | 1 |
| Dormer, BA | 2 |
| Theodore, A | 1 |
| Wolff, M | 1 |
| Kraan, JK | 1 |
| Mulder, RJ | 1 |
| van Dijk, B | 1 |
| Havel, A | 1 |
| Rosenfeld, M | 1 |
| Mayer, E | 1 |
| Salamandra, IA | 1 |
| Salinger, PL | 1 |
| Adnitt, PI | 1 |
| Evans, DA | 1 |
| Nesbitt, GH | 1 |
| Rosa, WA | 1 |
| Niec, R | 1 |
| Lukovich, R | 1 |
| San Martin, LA | 1 |
| Echenique, JA | 1 |
| Tacquet, A | 1 |
| Devulder, B | 1 |
| Tison, F | 1 |
| Martin, JC | 1 |
| Orlowski, EH | 1 |
| Jones, LD | 1 |
| Fairchild, DG | 1 |
| Morse, WC | 1 |
| Kollmeier, H | 1 |
| Ilgner, M | 1 |
| Voss, H | 1 |
| Winkler, E | 1 |
| Daddi, G | 1 |
| Lucchesi, M | 2 |
| Mancini, P | 2 |
| Matzeu, M | 1 |
| Toth, B | 2 |
| Glass, F | 1 |
| Mallach, HJ | 1 |
| Shubik, P | 1 |
| Harper, KH | 1 |
| Worden, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients[NCT00801606] | Phase 3 | 403 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers[NCT03892161] | Phase 1 | 17 participants (Actual) | Interventional | 2018-04-12 | Terminated (stopped due to Risks to participation) | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for isoniazid and Body Weight
| Article | Year |
|---|---|
Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Genotype; Humans; Isoniazi | 2022 |
Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
Topics: Africa; Anti-HIV Agents; Antitubercular Agents; Asia; Body Weight; Central Nervous System Diseases; | 2018 |
Ethambutol and viomycin.
Topics: Adolescent; Aged; Body Weight; Child, Preschool; Cycloserine; Deafness; Ethambutol; Female; Humans; | 1970 |
13 trials available for isoniazid and Body Weight
| Article | Year |
|---|---|
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Arylamine N-Acetyltransferase; B | 2021 |
Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Dose-Response | 2019 |
Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial.
Topics: Adolescent; Antitubercular Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschoo | 2014 |
Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.
Topics: Adult; Antitubercular Agents; Blood Sedimentation; Body Weight; Chemical and Drug Induced Liver Inju | 2008 |
Lack of weight gain and relapse risk in a large tuberculosis treatment trial.
Topics: Adult; Antitubercular Agents; Body Mass Index; Body Weight; Female; Humans; Isoniazid; Male; Middle | 2006 |
A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Black People; Body Weight; Drug Administration Sched | 1996 |
[A pilot and a controlled study of the influence of ethambutol on serum urate concentration and uric acid clearance (author's transl)].
Topics: Alcoholism; Body Weight; Creatinine; Ethambutol; Humans; Isoniazid; Rifampin; Streptomycin; Tubercul | 1979 |
Rifampicin plus isoniazid, rifampicin plus PAS, and isoniazid plus PAS in the initial treatment of pulmonary tuberculosis. A controlled multicenter clinical trial.
Topics: Adult; Aminosalicylic Acids; Blood Proteins; Blood Sedimentation; Body Weight; Clinical Trials as To | 1974 |
A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice-weekly isoniazid plus streptomycin or daily isoniazid plus pas.
Topics: Aminosalicylic Acids; Body Weight; Clinical Trials as Topic; Drug Resistance, Microbial; Follow-Up S | 1969 |
Comparative controlled trial of rimactane in pulmonary tuberculosis.
Topics: Adolescent; Adult; Blood Sedimentation; Body Weight; Clinical Trials as Topic; Drug Synergism; Femal | 1969 |
The effect of isoniazid on performance in school.
Topics: Achievement; Adolescent; Age Factors; Body Weight; Child; Clinical Trials as Topic; Ethnicity; Femal | 1970 |
Controlled study on rifampicin in first treatment of fresh cases of pulmonary tuberculosis.
Topics: Body Weight; Clinical Trials as Topic; Drug Synergism; Ethambutol; Humans; Isoniazid; Rifampin; Stre | 1969 |
Rifampicin, ethambutol, ethionamide and hydronsan in advanced pulmonary tuberculosis.
Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubi | 1972 |
69 other studies available for isoniazid and Body Weight
| Article | Year |
|---|---|
A novel synthesis of 2-arylbenzimidazoles in molecular sieves-MeOH system and their antitubercular activity.
Topics: Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Binding Sites; Body Weight | 2018 |
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Therapy, Combination; | 2023 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
[Relationship between the weight of hospitalized patients with pulmonary tuberculosis and the oral dose of isoniazid].
Topics: Administration, Oral; Adult; Aged; Antitubercular Agents; Body Weight; Drug Dosage Calculations; Fem | 2018 |
Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.
Topics: Algorithms; Antitubercular Agents; Body Weight; Child Nutrition Disorders; Child, Preschool; Drug Ad | 2019 |
A comparison of hepatoprotective activity of Bacoside to Silymarin treatment against a combined Isoniazid and Rifampin-induced hepatotoxicity in female Wistar rats.
Topics: Animals; Antioxidants; Bacopa; Body Weight; Chemical and Drug Induced Liver Injury; Female; Isoniazi | 2019 |
Circadian-time dependent tolerance and haematological toxicity to isoniazid in murine.
Topics: Animals; Blood Cell Count; Body Temperature; Body Weight; Cell Lineage; Circadian Rhythm; Drug Toler | 2015 |
A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
Topics: Adult; Aged; Algorithms; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Dos | 2015 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
Topics: Antitubercular Agents; Body Weight; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; | 2015 |
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
Topics: Antitubercular Agents; Area Under Curve; Body Weight; Dose-Response Relationship, Drug; Drug Monitor | 2016 |
Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Body Weight; Drug Monitoring; Fe | 2011 |
Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.
Topics: Antitubercular Agents; Area Under Curve; Body Weight; Drug Dosage Calculations; Ethnicity; Female; H | 2012 |
Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations | 2012 |
Nitrogen metabolism and food intake in nontuberculous patients receiving isoniazid.
Topics: Appetite; Body Weight; Eating; Humans; Isoniazid; Niacin; Nicotinic Acids; Nitrogen | 1953 |
Isoniazid and weight gain: a pilot investigation.
Topics: Body Weight; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary; Weight Gain | 1954 |
[Supposed mechanism of weight-increasing effect of isonicotinic acid hydrazide].
Topics: Body Weight; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
ORAL OUT-PATIENT CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN WEST AFRICANS.
Topics: Africa; Africa, Western; Aminosalicylic Acid; Aminosalicylic Acids; Body Weight; Drug Resistance; Dr | 1963 |
MONOTHERAPY WITH 4-4'DIISOAMYLOXYTHIO-CARBANILIDE (ISOXYL).
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Biomedical Research; Blood Sedimen | 1964 |
EFFECTS OF CHLORTETRACYCLINE AND ISONIAZID ON BODY WEIGHT GAIN AND INTESTINAL UREA HYDROLYSIS OF RATS.
Topics: Body Weight; Chlortetracycline; Hydrolysis; Intestines; Isoniazid; Metabolism; Pharmacology; Rats; R | 1964 |
[Increase of weight in infant dystrophy following isoniazid therapy].
Topics: Body Weight; Humans; Infant Nutrition Disorders; Isoniazid; Niacin; Nicotinic Acids | 1955 |
The role of diet in the treatment of pulmonary tuberculosis. An evaluation in a controlled chemotherapy study in home and sanatorium patients in South India.
Topics: Antitubercular Agents; Body Weight; Diet; Disease Management; Humans; India; Isoniazid; Nutrition As | 1961 |
Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Area Under Curve; Body Weight; Ethambutol; Humans; I | 2003 |
Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Weight; Commun | 2004 |
Effect of different oral doses of isoniazid-rifampicin in rats.
Topics: Administration, Oral; Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferas | 2006 |
Studies of the toxicity of isonicotinic acid hydrazide (isoniazid) to ducklings.
Topics: Animals; Body Weight; Diet; Ducks; Isoniazid; Male | 1967 |
Intermittent chemotherapy with isoniazid and streptomycin in Algiers.
Topics: Adolescent; Adult; Aged; Algeria; Ambulatory Care; Body Weight; Drug Resistance, Microbial; Female; | 1967 |
Effects of benserazide, carbidopa and isoniazid administration on tryptophan-nicotinamide nucleotide metabolism in the rat.
Topics: Animals; Benserazide; Body Weight; Carbidopa; Diet; Hydrazines; Isoniazid; Liver; Male; Niacinamide; | 1980 |
Isonicotinic acid hydrazide: early effects on peripheral nerve conduction velocity.
Topics: Animals; Body Weight; Isoniazid; Kinetics; Nervous System Diseases; Neural Conduction; Peripheral Ne | 1984 |
[Formula for calculating the effective dose of isoniazid].
Topics: Body Weight; Humans; Isoniazid; Mathematics; Time Factors | 1980 |
Drug therapy of bacillus Calmette-Guérin sepsis.
Topics: Animals; Body Weight; Cycloserine; Drug Combinations; Isoniazid; Mice; Mice, Inbred C3H; Mycobacteri | 1995 |
Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Body Weight; Drug Administratio | 1994 |
Tuberculosis control programme guidelines--treatment regimens.
Topics: Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; | 1996 |
Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Mass Index; Body Weight; Drug Therap | 1999 |
Isoniazid- and rifampicin-induced oxidative hepatic injury--protection by N-acetylcysteine.
Topics: Acetylcysteine; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Catalase; C | 2000 |
Effect of diphenylhydantoin on the apposition of dentin. An experimental study in the rat.
Topics: Alkaline Phosphatase; Animals; Body Weight; Calcium; Cholecalciferol; Connective Tissue; Dentinogene | 1977 |
[The different inactivation of isoniazid in intermittent chemotherapy (author's transl)].
Topics: Adult; Aged; Biotransformation; Body Weight; Drug Resistance, Microbial; Female; Humans; Isoniazid; | 1977 |
Safety and efficacy of living BCG or BCG cell walls (CW) in the treatment of guinea pig hepatoma.
Topics: Animals; BCG Vaccine; Body Weight; Cell Wall; Graft Rejection; Guinea Pigs; Isoniazid; Liver Neoplas | 1979 |
[Incidence of pulmonary tuberculosis in diabetics (author's transl)].
Topics: Adult; Body Weight; Diabetes Complications; Female; Humans; Isoniazid; Male; Middle Aged; Radiograph | 1975 |
Isoniazid: behavioral and biochemical effects in rhesus monkeys.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Behavior, Animal; Body Weight; Haplorhin | 1976 |
[Acute isoniazid poisoning].
Topics: Adult; Body Weight; Female; Humans; Isoniazid; Male; Poisoning; Tuberculosis | 1976 |
Toxicological study of pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity.
Topics: Administration, Oral; Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferas | 1991 |
Classification of children as slow or rapid acetylators based on concentrations of isoniazid in saliva following oral administration of body-weight and surface-area-related dosages of the drug.
Topics: Acetylation; Acetyltransferases; Administration, Oral; Body Surface Area; Body Weight; Child; Child, | 1990 |
Effects of treatment with phenobarbitone or isoniazid on hepatotoxicity due to prolonged subanaesthetic halothane inhalation.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Halothane; Isoniazid; Liver; Male; Org | 1988 |
Halothane hepatotoxicity in Fischer 344 rats pretreated with isoniazid.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cytochrome P-450 Enzyme Sys | 1987 |
Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase.
Topics: Antitubercular Agents; Body Weight; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifa | 1986 |
Impairment of isoniazid clearance by propranolol.
Topics: Adolescent; Adult; Body Weight; Humans; Isoniazid; Male; Metabolic Clearance Rate; Propranolol | 1985 |
Gastrointestinal tuberculosis.
Topics: Adult; Aminosalicylic Acids; Appendicitis; Blood Sedimentation; Body Weight; Cecum; Child; Cholecyst | 1973 |
Undiagnosed tuberculosis in a general hospital.
Topics: Adult; Age Factors; Aged; Aminosalicylic Acids; Biopsy; Body Weight; Bone Marrow; Ethambutol; Fatigu | 1972 |
A controlled comparison of self-administered versus supervised treatment in Singapore.
Topics: Age Factors; Ambulatory Care; Aminosalicylic Acids; Body Weight; Hospitalization; Humans; Isoniazid; | 1972 |
Severe cardiac failure in a chronic alcoholic.
Topics: Alcoholism; Autopsy; Body Weight; Cardiomyopathies; Chronic Disease; Diabetes Complications; Diagnos | 1973 |
Isoniazid inactivation in Indian children.
Topics: Age Factors; Body Weight; Child; Child, Preschool; Female; Humans; India; Infant; Isoniazid; Male; M | 1973 |
Further studies on the pharmacology of a slow-release matrix preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis.
Topics: Adult; Aged; Body Weight; Delayed-Action Preparations; Humans; Hydrazines; Isoniazid; Middle Aged; S | 1973 |
[Inhibition of isoniazid activity in the presence of chloroquinum diphosphoricum].
Topics: Animals; Body Weight; Chloroquine; Depression, Chemical; Drug Antagonism; Isoniazid; Mice; Mycobacte | 1970 |
Conversion by isoniazid of hyperacute to chronic pulmonary tuberculosis in mice. I. Survival times of mice and course of the chronic disease; bacterial populations and responses of the host.
Topics: Acute Disease; Animals; Body Weight; Cell Differentiation; Cells, Cultured; Chronic Disease; Colony | 1967 |
A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association.
Topics: Adult; Aged; Bilirubin; Body Weight; Drug Tolerance; Ethionamide; Feeding and Eating Disorders; Fema | 1968 |
Monoamineoxidase inhibition and insulin sensitivity.
Topics: Animals; Body Weight; Drug Synergism; Feeding and Eating Disorders; Growth Hormone; Humans; Hydrazin | 1968 |
Genetic variations in the acetylation of isoniazid and other drugs.
Topics: Adult; Aminobenzoates; Aminosalicylic Acids; Asian People; Black People; Body Weight; Depression; Fe | 1968 |
Evaluation of certain factors related to subclinical parasitism in cattle in Argentina.
Topics: Animals; Anthelmintics; Body Weight; Cattle; Cattle Diseases; Feces; Intestinal Diseases, Parasitic; | 1970 |
[Activity of Isoxyl on Mycobacterium kansasii; studies in vitro and in the pneumoconiotic guinea pig].
Topics: Administration, Oral; Animals; Body Weight; Drug Combinations; Ethambutol; Ethionamide; Guinea Pigs; | 1970 |
[Standard therapy of tuberculosis].
Topics: Antitubercular Agents; Body Weight; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Hum | 1971 |
The induction of pulmonary neoplasms in mice by isonicotinic acid hydrazide.
Topics: Animal Feed; Animals; Arginine; Body Weight; Carcinogens; Cell Nucleus; Cytoplasm; Feeding Behavior; | 1971 |
[Silicotuberculosis and ethambutol treatment].
Topics: Aged; Alkaline Phosphatase; Antitubercular Agents; Blood Proteins; Body Weight; Drug Resistance, Mic | 1968 |
[Intermittent rifomycin therapy of experimental tuberculosis in guinea pigs].
Topics: Animals; Body Weight; Drug Synergism; Ethambutol; Guinea Pigs; Isoniazid; Rifampin; Tuberculosis | 1968 |
[Intermittent ethambutol therapy of experimental tuberculosis in guinea pigs].
Topics: Animals; Body Weight; Drug Synergism; Ethambutol; Guinea Pigs; Isoniazid; Tuberculosis | 1968 |
Lung tumor induction and inhibition of breast adenocarcinomas by hydrazine sulfate in mice.
Topics: Adenocarcinoma; Animals; Body Weight; Carcinoma; Depression, Chemical; Female; Hydrazines; Isoniazid | 1969 |
[Animal experimental studies on alcohol effects after sustained loading with isonicotinic acid hydrazide].
Topics: Alcohols; Animals; Body Weight; Drug Synergism; Isoniazid; Mice | 1965 |
Mammary tumor inhibition and lung adenoma induction by isonicotinic acid hydrazide.
Topics: Adenocarcinoma; Adenoma; Animals; Body Weight; Carcinogens; Female; Isoniazid; Lung Neoplasms; Male; | 1966 |
Comparative toxicity of isonicotinic acid hydrazide and its methanosulfonate derivative.
Topics: Alkaline Phosphatase; Animals; Blood Proteins; Body Weight; Female; Guinea Pigs; Isoniazid; Liver; M | 1966 |